Affordable Access

Itraconazole in the management of chronic dermatophytosis.

Authors
  • Hay, R J1
  • Clayton, Y M
  • Moore, M K
  • Midgely, G
  • 1 Mycology Department, St. John's Hospital for Diseases of the Skin, London, United Kingdom. , (United Kingdom)
Type
Published Article
Journal
Journal of the American Academy of Dermatology
Publisher
Elsevier
Publication Date
Sep 01, 1990
Volume
23
Issue
3 Pt 2
Pages
561–564
Identifiers
PMID: 2170475
Source
Medline
License
Unknown

Abstract

Fifty-five patients with griseofulvin-unresponsive dermatophytosis caused by Trichophyton rubrum were treated with itraconazole. They had either tinea corporis or "dry type" infections of the palms, soles, or nails. The following sites were affected: trunk (12 infections), soles (47), toe webs (52), palms (26), fingernails (29), and toenails (42). Patients were treated with oral itraconazole until clinical and mycologic remission were achieved. Response rates and mean times to recovery were as follows: trunk, 100%, 1.5 months; soles, 83%, 6.7 months; toe webs, 90%, 7.2 months; palms, 96%, 4.6 months; fingernails, 90%, 5.4 months; and toenails, 76%, 10.3 months). In a 6-month follow-up period 7 of 30 patients with toenail infections who had responded to treatment had a clinical and mycologic relapse, usually of one nail. Side effects were minimal but included abdominal discomfort (three patients), headache (one), and weight gain (two). No persistent abnormalities in blood biochemistry were seen, even in patients who received itraconazole for more than 9 months.

Report this publication

Statistics

Seen <100 times